Last reviewed · How we verify
Triamcinolone Hexacetonide and hyaluronic acid
At a glance
| Generic name | Triamcinolone Hexacetonide and hyaluronic acid |
|---|---|
| Also known as | Cingal |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Urinary tract infection
- Headache
- Joint swelling
- Injection site pain
- COVID-19
- Arthropod sting
- Back pain
- Bursitis
- Osteoarthritis
- Hypothyroidism
- Abdominal pain upper
Key clinical trials
- Intra-articular Corticosteroid With Hyaluronic Acid Plus Physiotherapy for Hip Pathologies (NON-OP HIP) (NA)
- Additional Effect of Steroid on Hyaluronic Acid in Subdeltoid Bursitis (PHASE4)
- Three Different Modalities for Treatment of Inflammatory Punctal Stenosis (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint (NA)
- Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers (NA)
- Comparison of the Analgesic Effect of 2 Shoulder Infiltrations (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: